financetom
Business
financetom
/
Business
/
DigitalOcean Q2 Non-GAAP Net Income, Revenue Rise; Full-Year Guidance Lifted
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
DigitalOcean Q2 Non-GAAP Net Income, Revenue Rise; Full-Year Guidance Lifted
Aug 5, 2025 6:10 AM

08:40 AM EDT, 08/05/2025 (MT Newswires) -- DigitalOcean ( DOCN ) reported Q2 non-GAAP net income Tuesday of $0.59 per diluted share, up from $0.48 a year earlier.

Analysts polled by FactSet expected $0.47.

Revenue for the quarter ended June 30 was $218.7 million, up from $192.5 million a year earlier.

Analysts surveyed by FactSet expected $216.6 million.

The company said it expects Q3 non-GAAP net income of $0.45 to $0.50 per diluted share on total revenue of $226 million to $227 million. Analysts surveyed by FactSet expect $0.47 and $223.6 million, respectively.

DigitalOcean ( DOCN ) said it now expects its full-year 2025 non-GAAP net income to be in a range of $2.05 to $2.10 per diluted share, up from the previous range of $1.85 to $1.95. Total revenue for the year is now expected to be in a range of $888 million to $892 million, compared with the previous range of $870 million to $890 million. Analysts polled by FactSet expect EPS of $1.95 on revenue of $881.9 million.

The company's shares were up more than 8% in recent Tuesday premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes
FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes
Nov 4, 2024
Oct 31 (Reuters) - Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' ( LXRX ) add-on treatment to insulin therapy for managing blood glucose levels in adults with type 1 diabetes and chronic kidney disease. The panel voted 11 to 3 against recommending the drug, chemically known as sotagliflozin. ...
Ingersoll Rand Q3 Adjusted Earnings, Revenue Rise; Full Year Guidance Revised
Ingersoll Rand Q3 Adjusted Earnings, Revenue Rise; Full Year Guidance Revised
Nov 4, 2024
04:50 PM EDT, 10/31/2024 (MT Newswires) -- Ingersoll Rand ( IR ) reported Q3 adjusted diluted earnings late Thursday of $0.84 per share, up from $0.77 a year earlier. Analysts polled by Capital IQ expected $0.81. Revenue for the quarter ended Sept. 30 was $1.86 billion, up from $1.74 billion a year ago. Analysts surveyed by Capital IQ expected $1.87...
Amphenol Insider Sold Shares Worth $5,159,738, According to a Recent SEC Filing
Amphenol Insider Sold Shares Worth $5,159,738, According to a Recent SEC Filing
Nov 4, 2024
04:50 PM EDT, 10/31/2024 (MT Newswires) -- Lance E D'Amico, Sr. VP, Secretary & Gen. Counsel, on Oct. 30, sold 75,000 shares in Amphenol ( APH ) for $5,159,738. Following the Form 4 filing with the SEC, D'Amico has control over a total of 76,400 shares of the company, with 76,400 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/820313/000112760224026153/xslF345X05/form4.xml Price: 67.05, Change:...
Amazon Tops Third-Quarter Views as Cloud Computing, Advertising Sales Gain
Amazon Tops Third-Quarter Views as Cloud Computing, Advertising Sales Gain
Nov 4, 2024
04:49 PM EDT, 10/31/2024 (MT Newswires) -- Amazon ( AMZN ) late Thursday reported third-quarter results that surpassed Wall Street's estimates as the e-commerce giant logged double-digit revenue gains for its cloud-computing platform and advertising business. Per-share earnings jumped to $1.43 for the quarter through Sept. 30 from $0.94 a year earlier, topping the Capital IQ-polled GAAP consensus of $1.14....
Copyright 2023-2026 - www.financetom.com All Rights Reserved